Navigation Links
Optimer Reports Fourth Quarter and Fiscal Year 2011 Financial Results
Date:3/7/2012

e DIFICLIR™. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Forward-Looking Statements Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation statements related to Optimer's expectations of future sales and adoption of DIFICID, projections regarding the results and trends of the DIFICID launch and expected label expansion as a result of new development efforts and clinical trials. Words such as "believes", "would", "anticipates", "plans", "expects", "may", "intend", "will", and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on management's expectations on the date of this release. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: Optimer's ability to continue driving adoption and use of DIFICID, the implementation and success of DIFICID growth initiatives and entry into new markets, the ability to expand indications included on DIFICID's label, the ability to successfully complete additional clinical trials and  whether such trials will support an expanded label for DIFICID, whether healthcare professionals will prescribe DIFICID, the extent to which DIFICID receives reimbursement coverage from healthcare payers and government agencies, the extent to which DIFICID will be accepted on a
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results
2. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
3. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
4. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
5. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
7. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
8. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
9. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
10. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
11. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)... -- Echo Therapeutics, Inc. (NASDAQ: ECTE ... permeation, continuous glucose monitoring and associated technologies, today ... been appointed Chief Executive Officer effective December 22, ... of experience in the medical device, pharmaceutical and ... Vice President, Business Development, Otsuka Pharmaceuticals as well as ...
(Date:12/24/2014)... 24, 2014 LifeScienceIndustryResearch.com ... Disposable Syringe Industry of 178 pages providing ... intelligence library. The 2014 Market ... is a professional and deep research report ... analysis, the report introduces Disposable Syringe basic ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Verinata Health, Inc., a privately-held company dedicated to maternal ... corporate headquarters and laboratory operations to 800 Saginaw Drive, ... a much larger and state-of-the art facility is a ... growth and expansion expected with the launch of our ...
... PITTSBURGH, Dec. 7, 2011 HealthpointCapital, LLC ("HealthpointCapital") ... Inc. ("Blue Belt" or "Company"). Blue Belt is ... for use initially in orthopedic procedures and then ... ("ENT"). Terms of the transaction were not disclosed. ...
Cached Medicine Technology:Verinata Health Announces New Corporate Headquarters and Expanded Laboratory Operations 2HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO 2
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... CAGR of 7.2% to reach $5,756.0 million by ... the microscopy market. The electron microscopes product segment ... the forecast period. , Rising focus on nanotechnology, ... growth of the microscopy market. , Get Full ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... December 26, 2014 The report “TS-1 ... focuses on the current treatment landscape, unmet needs, current ... TS-1 is an anti-cancer drug which is typically used ... is also used for treating gastric cancer and pancreatic ... potassium. The drug was first approved in 1999 in ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... be one of the hottest styles in the next few ... company releases 26 A-line sweetheart evening dresses, and announces the ... “We are trying our best to help a lady to ... with affordable prices, we provide discounted delivery costs to our ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online ... its collection of discounted prom dresses, most of which ... spokesman of the company, the promotion is valid until ... to expand the UK market. , The prom dresses ... lengths, and styles: A-line strapless, empire strapless chiffon, one ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... estrogen therapy does not decrease, but may increase, the ... studies have reported an association between postmenopausal estrogen use ... of estrogen or estrogen plus progestin in women aged ... dementia. In the estrogen-only trial, researchers found 47 participants ...
... the body. Parkinson's patients are particularly at risk for ... a drug commonly used to treat the disease, produces ... patients with Parkinson’s disease who have high levels of ... worse cognitive functioning than other patients who have normal ...
... about 40 milligrams of vitamin C daily as new ... may protect against rheumatoid arthritis. ,Researchers studied 23,000 ... 74. Participants' diets were assessed by using seven-day-food-intake diaries.It ... or more joints for at least one month and ...
... symptoms of rheumatoid arthritis as well as keep cardiovascular ... have an anti-inflammatory effect and are well-known for reducing ... puts sufferers at an increased risk of cardiovascular disease. ... day of atorvastatin or a placebo in addition to ...
... testicles and cause prostate cancer cells to grow. Lowering ... grow more slowly. However, hormone therapy will not cure ... such as surgery or radiation are not good options. ... cancer significantly increases the risk of fractures.For the study ...
... be risking bone loss say researchers. Investigators tested post-menopausal women ... likely to have lower scores on heel and hip tests ... ,More than 6,000 women participated in the study.The loss ... both the heel bone and the hip. Those numbers held ...
Cached Medicine News:
... Solution offers relief from CTS pain and ... from other over-the-counter CTS treatments. It is ... sleep, the Carpal Solution gently reshapes soft ... and eliminates hand pain, numbness and sleep ...
... ESR-10 Manual Rack is a manual ... the erythrocyte sedimentation rate (ESR) of ... 1.2ml Streck ESR-Vacuum Tubes. The rack ... simultaneously. The ESR-10 Manual Rack exhibits ...
... assayed control for immunophenotyping with Beckman Coulter® ... the accuracy and reproducibility of all the ... including red blood cell lysis. Reference values ... lymphocytes, B lymphocytes, granulocytes, monocytes, and NK ...
... Cyto-Chex is a storage ... preserve the white blood cells ... activity of antigenic sites. Samples ... stored for up to seven ...
Medicine Products: